Active targeting of mesoporous silica drug carriers enhances γ-secretase inhibitor efficacy in an in vivo model for breast cancer.
暂无分享,去创建一个
Felicitas Genze | Rainer Wittig | Cecilia Sahlgren | Jessica M Rosenholm | J. Rosenholm | M. Lindén | E. von Haartman | C. Sahlgren | L. Bergman | T. Simmet | R. Wittig | J. Hemming | Thomas Simmet | Mika Lindén | Jarl Hemming | Eva von Haartman | Lotta Bergman | F. Genze
[1] Y. Maitani,et al. Folate-linked nanoparticle-mediated suicide gene therapy in human prostate cancer and nasopharyngeal cancer with herpes simplex virus thymidine kinase , 2005, Cancer Gene Therapy.
[2] J. Rosenholm,et al. Amino-functionalization of large-pore mesoscopically ordered silica by a one-step hyperbranching polymerization of a surface-grown polyethyleneimine. , 2006, Chemical communications.
[3] M. Bissell,et al. Of extracellular matrix, scaffolds, and signaling: tissue architecture regulates development, homeostasis, and cancer. , 2006, Annual review of cell and developmental biology.
[4] J. Eriksson,et al. Targeted intracellular delivery of hydrophobic agents using mesoporous hybrid silica nanoparticles as carrier systems. , 2009, Nano letters.
[5] Juergen Friedrich,et al. Experimental anti-tumor therapy in 3-D: Spheroids – old hat or new challenge? , 2007, International journal of radiation biology.
[6] Ze Lu,et al. Improving delivery and efficacy of nanomedicines in solid tumors: role of tumor priming. , 2011, Nanomedicine.
[7] James P. Quigley,et al. Chick embryo chorioallantoic membrane model systems to study and visualize human tumor cell metastasis , 2008, Histochemistry and Cell Biology.
[8] U. Bhanot,et al. Small molecule XIAP inhibitors enhance TRAIL-induced apoptosis and antitumor activity in preclinical models of pancreatic carcinoma. , 2009, Cancer research.
[9] M. Katsogiannou,et al. Active-targeted nanotherapy strategies for prostate cancer. , 2011, Current cancer drug targets.
[10] E. Ruoslahti,et al. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. , 1998, Science.
[11] Jessica M. Rosenholm and,et al. Wet-Chemical Analysis of Surface Concentration of Accessible Groups on Different Amino-Functionalized Mesoporous SBA-15 Silicas , 2007 .
[12] L. Sillerud,et al. Prostate cancer targeting motifs: Expression of ανβ3, neurotensin receptor 1, prostate specific membrane antigen, and prostate stem cell antigen in human prostate cancer cell lines and xenografts , 2012, The Prostate.
[13] William C Hines,et al. Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression , 2011, Nature Medicine.
[14] Chindo Hicks,et al. Cross-talk between notch and the estrogen receptor in breast cancer suggests novel therapeutic approaches. , 2008, Cancer research.
[15] J. Eriksson,et al. Cancer-cell-specific induction of apoptosis using mesoporous silica nanoparticles as drug-delivery vectors. , 2010, Small.
[16] Rasmus Niemi,et al. Targeting of porous hybrid silica nanoparticles to cancer cells. , 2009, ACS nano.
[17] Cecilia Sahlgren,et al. Mesoporous silica nanoparticles as drug delivery systems for targeted inhibition of Notch signaling in cancer. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.
[18] Minhong Yan,et al. Chronic DLL4 blockade induces vascular neoplasms , 2010, Nature.
[19] Benjamin Purow,et al. Notch inhibition as a promising new approach to cancer therapy. , 2012, Advances in experimental medicine and biology.
[20] C. M. Roth,et al. Nanoscale drug delivery systems for enhanced drug penetration into solid tumors: current progress and opportunities. , 2012, Critical reviews in biomedical engineering.
[21] Laurence Raehm,et al. Cancer therapy improvement with mesoporous silica nanoparticles combining targeting, drug delivery and PDT. , 2012, International journal of pharmaceutics.
[22] M. Maynadier,et al. Multifunctionalized mesoporous silica nanoparticles for the in vitro treatment of retinoblastoma: Drug delivery, one and two-photon photodynamic therapy. , 2012, International journal of pharmaceutics.
[23] D. Ribatti,et al. In vivo inhibition of human hepatocellular carcinoma related angiogenesis by vinblastine and rapamycin. , 2007, Histology and histopathology.
[24] Daniel A. Heller,et al. Treating metastatic cancer with nanotechnology , 2011, Nature Reviews Cancer.
[25] S. Morrison,et al. Targeting, Imaging, and Therapy Using a Humanized Antiprostate Stem Cell Antigen (PSCA) Antibody , 2007, Journal of immunotherapy.
[26] U. Lendahl,et al. Notch signaling mediates hypoxia-induced tumor cell migration and invasion , 2008, Proceedings of the National Academy of Sciences.
[27] Jay S. Fine,et al. Chronic Treatment with the γ-Secretase Inhibitor LY-411,575 Inhibits β-Amyloid Peptide Production and Alters Lymphopoiesis and Intestinal Cell Differentiation* , 2004, Journal of Biological Chemistry.
[28] S. Christensen,et al. Engineering a Prostate-Specific Membrane Antigen–Activated Tumor Endothelial Cell Prodrug for Cancer Therapy , 2012, Science Translational Medicine.
[29] Pauliina Kronqvist,et al. Hypo- and hyperactivated Notch signaling induce a glycolytic switch through distinct mechanisms , 2011, Proceedings of the National Academy of Sciences.
[30] A. Harris,et al. Targeting DLL4 in tumors shows preclinical activity but potentially significant toxicity. , 2010, Future oncology.
[31] J. Karp,et al. Nanocarriers as an Emerging Platform for Cancer Therapy , 2022 .
[32] V. Adhami,et al. Targeted Knockdown of Notch1 Inhibits Invasion of Human Prostate Cancer Cells Concomitant with Inhibition of Matrix Metalloproteinase-9 and Urokinase Plasminogen Activator , 2009, Clinical Cancer Research.
[33] Gert Storm,et al. Sheddable Coatings for Long-Circulating Nanoparticles , 2007, Pharmaceutical Research.
[34] Neetu Singh,et al. Nanoparticles that communicate in vivo to amplify tumour targeting. , 2011, Nature materials.
[35] M. Maynadier,et al. Mannose-functionalized mesoporous silica nanoparticles for efficient two-photon photodynamic therapy of solid tumors. , 2011, Angewandte Chemie.
[36] Cecilia Sahlgren,et al. Nanoparticles in targeted cancer therapy: mesoporous silica nanoparticles entering preclinical development stage. , 2012, Nanomedicine.
[37] R. Hautmann,et al. Chorioallantoic membrane assay: vascularized 3-dimensional cell culture system for human prostate cancer cells as an animal substitute model. , 2001, The Journal of urology.
[38] Meena Mahmood,et al. Engineered nanostructural materials for application in cancer biology and medicine , 2012, Journal of applied toxicology : JAT.
[39] S. Rayala,et al. Nanomedicine: towards development of patient-friendly drug-delivery systems for oncological applications , 2012, International journal of nanomedicine.
[40] S. Vinogradov,et al. Cancer stem cells and drug resistance: the potential of nanomedicine. , 2012, Nanomedicine.
[41] H. Schneckenburger,et al. Light exposure and cell viability in fluorescence microscopy , 2012, Journal of microscopy.
[42] Robert Langer,et al. Nanoparticle delivery of cancer drugs. , 2012, Annual review of medicine.
[43] Mina J Bissell,et al. Context, tissue plasticity, and cancer: are tumor stem cells also regulated by the microenvironment? , 2005, Cancer cell.
[44] Cecilia Sahlgren,et al. Mesoporous silica nanoparticles in medicine--recent advances. , 2013, Advanced drug delivery reviews.
[45] Ralph Weissleder,et al. Detection of early prostate cancer using a hepsin-targeted imaging agent. , 2008, Cancer research.
[46] R. Clarke,et al. Aberrant Activation of Notch Signaling in Human Breast Cancer , 2006 .
[47] R. Gurny,et al. Screening of nanoparticulate delivery systems for the photodetection of cancer in a simple and cost-effective model. , 2009, Nanomedicine.
[48] Robert Gurny,et al. The chick embryo and its chorioallantoic membrane (CAM) for the in vivo evaluation of drug delivery systems. , 2007, Advanced drug delivery reviews.
[49] R. Hibst,et al. Matrix-dependent regulation of AKT in Hepsin-overexpressing PC3 prostate cancer cells. , 2011, Neoplasia.
[50] S. Fulda,et al. Targeting XIAP bypasses Bcl-2-mediated resistance to TRAIL and cooperates with TRAIL to suppress pancreatic cancer growth in vitro and in vivo. , 2008, Cancer research.
[51] Jayanta Debnath,et al. Modeling morphogenesis and oncogenesis in three-dimensional breast epithelial cultures. , 2008, Annual review of pathology.
[52] Erkki Ruoslahti,et al. Targeting of drugs and nanoparticles to tumors , 2010, The Journal of cell biology.
[53] Paul Leonard,et al. Nanomedicine: barcodes check out prostate cancer. , 2010, Nature nanotechnology.
[54] Thomas Efferth,et al. Therapeutic and diagnostic applications of nanoparticles. , 2011, Current drug targets.
[55] Hans Clevers,et al. Notch/γ-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells , 2005, Nature.